This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Suzhou Galaxy Biopharma, Co., Ltd.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovations of Honglin Zhou
Introduction
Honglin Zhou is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on combating viral infections, specifically hepatitis C virus (HCV).
Latest Patents
Honglin Zhou holds a patent for a human monoclonal antibody known as 8D6, which targets HCV infection. This innovative antibody binds to the E2 subunit of the HCV capsid protein, effectively preventing the virus from infecting susceptible host cells. The patent outlines methods for producing various forms of genetic engineering antibodies using the antibody variable region gene or the complementary determining region (CDR) gene. These engineered antibodies can be produced in both prokaryotic and eukaryotic expression systems, offering potential therapeutic options for preventing or treating HCV infection. He has 1 patent to his name.
Career Highlights
Honglin Zhou is currently employed at Suzhou Galaxy Biopharma Co., Ltd., where he continues to advance his research in antibody development. His work has positioned him as a key figure in the biotechnology sector, contributing to the fight against viral diseases.
Collaborations
He collaborates with talented colleagues, including Jie Liu and Xin Dong, who share his commitment to innovation in the field of biopharmaceuticals.
Conclusion
Honglin Zhou's contributions to the development of therapeutic antibodies represent a significant advancement in the fight against hepatitis C virus infection. His innovative work continues to inspire progress in biotechnology and offers hope for effective treatments.